

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	D04X01
Policy Title	Amifampridine phosphate for the treatment of Lambert-Easton Myasthenic Syndrome
Accountable Commissioner	Carolyn Young
Clinical Reference Group	Neurosciences
Which stakeholders were contacted to be involved in policy development?	Neurosciences CRG membership and all registered stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable

FOR PUBLIC CONSULTATION ONLY

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	<p>None</p>
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for two weeks for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Three responses were received from CRG-registered stakeholders (one pharmacy association, one patient group and one individual response). No responses were received from CRG members.</p> <p>Key response themes were as follows:</p> <ol style="list-style-type: none"> (1) Several stakeholders requested for unpublished evidence to be considered in the evidence review (2) One of the respondents requested additional time for the 30 day period of public consultation (3) Additional stakeholders were identified to include in consultation (4) Stakeholders noted that an unlicensed version of Amifampridine Phosphate is in use.
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comment. No changes made to the evidence review or policy proposition. The additional identified stakeholder (ABN) will be invited to comment as part of public consultation.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders</p>